{"id":"W2078057935","doi":"10.1007/s10637-011-9722-5","title":"A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency","funders":"Bayer Canada","keywords":"Bicalutamide; Medicine; Sorafenib; Prostate cancer; Internal medicine; Oncology; Adverse effect; Clinical endpoint; Rash; Clinical trial; Cancer; Androgen receptor; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001411094,0.001859791,0.003869176,0.0007271494,0.0006362434,0.001241311,0.001045661,0.001213812,0.004030726],"category_scores_gemma":[0.00123838,0.001013063,0.002183112,0.0006947122,0.001472863,0.001475673,0.0004593873,0.004601578,0.001082551],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001033793,"about_ca_system_score_gemma":0.001949848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002008704,"about_ca_topic_score_gemma":0.005094491,"domain_scores_codex":[0.9993754,0.0002999014,0.00002942785,0.0001068338,0.00004414358,0.0001442998],"domain_scores_gemma":[0.9989711,0.000158563,0.0001205756,0.00008860965,0.0000566411,0.0006043734],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8629736,0.05618214,0.003404766,0.0007124795,0.00160846,0.0002453249,0.0003452315,0.002153439,0.01633751,0.0002325744,0.002206673,0.0535979],"study_design_scores_gemma":[0.6729148,0.3179205,0.005154358,0.00001859252,0.0004443275,0.0001667541,0.0000893457,0.000732431,0.001074043,0.0001198829,0.001328974,0.00003598865],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928126,0.002044889,0.0004710047,0.0005937749,0.0002544617,0.001726238,0.0006299393,0.0000814872,0.00138565],"genre_scores_gemma":[0.9916421,0.001999857,0.0009771188,0.0005089765,0.0002450969,0.001469897,0.001206844,0.00003470046,0.001915399],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004030726,"threshold_uncertainty_score":0.01348412,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03165917589675971,"score_gpt":0.3020189491864628,"score_spread":0.2703597732897031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}